Acceleron Pharma was officially acquired by Merck and Company, a major global healthcare and pharmaceutical leader, in a definitive all-cash transaction valued at approximately $11.5 billion. The strategic acquisition brought Acceleron's entire pipeline under Merck's corporate umbrella, allowing the pharmaceutical giant to expand its footprint into rare diseases and strengthen its long-term cardiovascular portfolio. Following customary regulatory clearances and overwhelming approval from shareholders, the multi-billion-dollar transaction was successfully finalized, integrating Acceleron as a wholly-owned subsidiary.
Acceleron Pharma earned strong acclaim as an exceptional, science-driven biopharmaceutical employer centered on groundbreaking rare disease and oncology research before being acquired by Merck.
Acceleron Pharma was a prominent clinical-stage biopharmaceutical enterprise focused on discovering, developing, and commercializing novel protein therapeutics targeted at treating serious and rare diseases, particularly focusing on pulmonary and hem...